X

Trial Profile

The effect of risedronate [risedronic acid] on bone turnover and bone mass in older men receiving neoadjuvant therapy for prostate cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risedronic acid (Primary)
Indications Bone resorption; Male osteoporosis
Focus Therapeutic Use

Most Recent Events

24 Jul 2012 Actual patient number changed from 40 to 50 as reported ClinicalTrials.gov.
07 Mar 2009 Trial phase, start and end dates, patient number, identifiers, sponsors and lead investigator and endpoints added from ClinicalTrials.gov.
07 Mar 2009 Status changed from not stated to completed, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com